Chugai Pharmaceutical Co ( (CHGCF) ) has released its Q1 earnings. Here is a breakdown of the information Chugai Pharmaceutical Co presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Chugai Pharmaceutical Co., Ltd. is a leading Japanese pharmaceutical company listed on the Tokyo Stock Exchange, primarily engaged in the research, development, manufacturing, and marketing of prescription medicines, with a strategic alliance with Roche Holding Ltd.
In its latest earnings report for the first quarter of 2025, Chugai Pharmaceutical reported significant growth across key financial metrics, showcasing a robust performance compared to the previous year.
The company achieved a revenue of ¥288.5 billion, marking a 21.8% increase year-on-year, driven by a 27% rise in sales. Operating profit surged by 36.8% to ¥136.7 billion, while net income rose by 30.7% to ¥97.2 billion. The growth was attributed to strong overseas sales, particularly the export of Hemlibra and Actemra to Roche, despite challenges in the domestic market due to drug price revisions and generic competition. Chugai also announced a special dividend in celebration of its 100th anniversary, contributing to a forecasted annual dividend of ¥250 per share.
Looking ahead, Chugai maintains a positive outlook for the fiscal year ending December 2025, with a slight increase in revenue and profit forecasts, reflecting confidence in its strategic initiatives and market position.